Isotype
Whole Humanized Antibody
Description
CDC-Enhanced Mepolizumab is a Fc-modified anti-IL-5 therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Mepolizumab, Mepolizumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Mepolizumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
This gene encodes a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. The encoded cytokine plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases. This cytokine functions by binding to its receptor, which is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). This gene is located on chromosome 5 within a cytokine gene cluster which includes interleukin 4 (IL4), interleukin 13 (IL13), and CSF2 . This gene, IL4, and IL13 may be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31
Alternative Names
EDF; TRF; IL-5
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Whole Humanized Antibody
Description
Mepolizumab is a humanized monoclonal antibody that specifically recognizes and blocks interleukin 5 (IL-5). It was approved by the US Food and Drug Administration (FDA) in 2007 for the treatment of severe eosinophilic asthma and is used in combination with other drugs for asthma. Mepolizumab is now used to treat many other conditions, such as severe nasal polyps, adult eosinophilic granuloma with polyangiitis (EGPA).
Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
